Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224763 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD
A Phase 1 study of Kidney Transplantation and ESRD (End-Stage Renal Disease), sponsored by United Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT07224763: Recruiting Phase 1 study of Kidney Transplantation and ESRD (End-Stage Renal Disease), sponsored by United Therapeutics.
NCT07224763 is a Phase 1 study of Kidney Transplantation and ESRD (End-Stage Renal Disease) that is actively recruiting participants, run by United Therapeutics. The registered enrollment target is 50 participants, below the 266-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07224763, a Phase 1 study of Kidney Transplantation and ESRD (End-Stage Renal Disease), is actively recruiting participants, sponsored by United Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2). The study consists of xenotransplantation followed by a 24-week Post-transplant Follow-up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, GGTA1 KO Thymokidney survival, and screening for zoonotic infections. Part B will continue for the lifetime of the participant or for 52 weeks following nephrectomy, if required.
Primary Outcome
Participant survival rate at 24 weeks post transplant.
Conditions Studied
Interventions
- BIOLOGICAL GGTA1 KO Thymokidney
Study Locations (1)
New York
- New York University Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-03 |
| Est. Completion | 2076-03 |
| Phase | Phase 1 |
What NCT07224763 shows while recruiting
NCT07224763 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 266-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (81% lower).
The record links to 3 conditions, with Kidney Transplantation appearing as the primary indexed condition, and to 1 intervention - of which GGTA1 KO Thymokidney is the first listed.
NCT07224763 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07224763 about?
NCT07224763 is a clinical study titled "Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD". The purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidn...
What is the current status of trial NCT07224763?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2026-03. Estimated completion is 2076-03.
What conditions does trial NCT07224763 study?
This clinical trial studies the following conditions: Kidney Transplantation, ESRD (End-Stage Renal Disease), Xenotransplantation.
What interventions are being tested in trial NCT07224763?
The interventions under investigation include: GGTA1 KO Thymokidney (BIOLOGICAL).
Who is sponsoring clinical trial NCT07224763?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07224763 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07224763's enrollment target sits among peer trials
50 22nd of 33 higher than 11 of 33 other Kidney Transplantation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Transplantation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD
RECRUITING · Phase 1
-
Tolerance by Engaging Antigen During Cellular Homeostasis
COMPLETED · Phase 1
-
CCFZ533X2201 - PoC Study in de Novo Renal Transplantation
COMPLETED · Phase 1
-
Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults
COMPLETED · Phase 1
-
Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.
RECRUITING · Phase 4
-
Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia